Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

This study has been completed.
Information provided by (Responsible Party):
Sprout Pharmaceuticals, Inc Identifier:
First received: October 15, 2009
Last updated: May 14, 2014
Last verified: May 2014
The objective of this trial is to assess the safety and efficacy of 24-week course of flibanserin for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in naturally postmenopausal women.

Condition Intervention Phase
Sexual Dysfunctions, Psychological
Drug: flibanserin
Drug: placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
Primary Purpose: Treatment
Official Title: 24-wk Efficacy and Safety of Flibanserin vs Pbo in Naturally Postmenopausal Women in United States

Resource links provided by NLM:

Further study details as provided by Sprout Pharmaceuticals, Inc:

Primary Outcome Measures:
  • Change From Baseline in the Number of Satisfying Sexual Events [ Time Frame: baseline through 24 weeks ]
    A small handheld electronic device (eDiary) was used by patients to record information about sexual events. Patients were instructed to complete the eDiary every morning. When completing an eDiary entry, patients answered questions regarding their sexual events since their last eDiary entry. If patients missed or were late with their eDiary entry, they could enter information about their sexual events since their most recent entry up to a maximum of seven days in the past.

  • Change From Baseline in the Score on the Female Sexual Function Index (FSFI) Desire Domain [ Time Frame: baseline through 24 weeks ]
    The FSFI© is a brief, self-administered questionnaire to assess key dimensions of sexual function in women. The scale consists of 19 items that assess sexual function over the past four weeks and yields scores in six domains: desire, arousal, lubrication, orgasm, satisfaction, and pain. The two items in the desire domain are scored from 1 to 5 (with 1 being the lowest report of desire and 5 being the highest). The raw scores of the two items are added together and then multiplied by the domain factor of 0.6. Thus, the score of the desire domain ranges from 1.2 to 6.0 (the higher the score, the higher the reported level of desire).

Secondary Outcome Measures:
  • Change From Baseline on Question 13 of the Female Sexual Distress Scale Revised (FSDS R) [ Time Frame: change from baseline to 24 weeks ]
    The FSDS© is a self-administered measure of female personal distress associated with sexual dysfunction. Question 13 inquires about distress specifically related to sexual desire. The range for each question, including Question 13, is 0 (Never) to 4 (Always).

Enrollment: 949
Study Start Date: October 2009
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: flibanserin 100mg
flibanserin 100mg po qd
Drug: flibanserin
patients will be randomized to flibanserin or placebo in a double-blind manner
Placebo Comparator: placebo
placebo one tablet po qd
Drug: placebo
patients will be randomized to flibanserin or placebo in a double-blind manner


Ages Eligible for Study:   35 Years and older   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Naturally postmenopausal women of any age with at least one ovary
  • Diagnosis of Hypoactive Sexual Desire Disorder, generalized acquired type,of at least six months duration
  • Stable, monogamous heterosexual relationship for at least one year
  • Willing to discuss sexual issues
  • Willing to engage in sexual activity at least once a month
  • Normal Pap smear
  • Normal mammogram
  • Normal uterine lining
  • Able to comply with daily use of handheld data entry device

Exclusion criteria:

  • Sexual dysfunctions other than HSDD, such as Sexual Aversion Disorder, Substance-induced Sexual Dysfunction, Dyspareunia, Vaginismus, Gender Identity Disorder, Paraphilia and Sexual Dysfunction due to a General Medical Condition
  • Partner with inadequately treated organic or psychosexual dysfunction
  • Sexual function impaired by psychiatric disorder
  • Sexual function impaired by gynecological disorder
  • Major Depression
  • Suicidal behavior or ideation
  • Major life stress that could impair sexual function
  • Substance abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00996372

  Show 75 Study Locations
Sponsors and Collaborators
Sprout Pharmaceuticals, Inc
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Sprout Pharmaceuticals, Inc Identifier: NCT00996372     History of Changes
Other Study ID Numbers: 511.130
Study First Received: October 15, 2009
Results First Received: February 26, 2014
Last Updated: May 14, 2014

Additional relevant MeSH terms:
Sexual Dysfunctions, Psychological
Mental Disorders processed this record on April 28, 2017